Iridex Publishes Peer-Reviewed Study In Ophthalmology Therapy; Highlights Safety And Efficacy Of MicroPulse Transscleral Laser Therapy In Managing Both Primary And Secondary Glaucoma Over Five Years.

Benzinga05:06

Iridex Announces Milestone Five-Year Study Confirms the Long-Term Effectiveness and Safety of MicroPulse Transscleral Cyclophotocoagulation for Glaucoma Management

GlobeNewswire05:05

Iridex Confirms That Local Coverage Determination L37531, Relating To Micro-Invasive Glaucoma Surgery Was Adopted As Scheduled And Wll Be Effective For Services Performed After Nov. 17

Benzinga11/19 21:20

Iridex Comments on Changing Glaucoma Reimbursement Landscape

GlobeNewswire11/19 21:14

IRIDEX Corporation (IRIX) Q3 2024 Earnings Call Transcript Summary

Futuニュース11/17 06:03

IRIDEX Corp (IRIX) Q3 2024 Earnings Call Highlights: Strategic Moves and Glaucoma Growth Amid ...

Yahoo Finance11/13 15:20